DDX39A: A Potential Drug Target and Biomarker for ALS-Related Neuronal Damage

Target Name: DDX39A

NCBI ID: G10212

DDX39A

DDX39A: A Potential Drug Target and Biomarker for ALS-Related Neuronal Damage

Amyloidosis, one of the most common forms of neurodegenerative diseases, has a significant impact on the lives of millions of people worldwide. The most common form of amyloidosis is Alzheimer's disease (AD), which is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. Other forms of amyloidosis, including primary amyloidosis and secondary amyloidosis, are less common but also have significant effects on the brain.

One of the leading causes of neurodegenerative diseases is the protein known as DDX39A.DDx39A is a protein that is expressed in the brain and has been shown to be involved in the development and progression of various neurological disorders, including ALS (Amyotrophic Lateral Sclerosis).

The Protein: Structural and Functional Characterization

DDX39A is a 21-kDa protein that is expressed in the brain and has been shown to localize to various regions of the brain, including the basal ganglia, a region of the brain responsible for motor movement and emotion regulation. It is composed of two major domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain.

The N-terminal transmembrane domain of DDX39A is characterized by a characteristic Rossmann (??) sheet, which is a common structural feature in proteins that are involved in cell signaling. The C-terminal cytoplasmic domain of DDX39A contains a number of potential interacting partners, including other proteins and nucleic acids.

Functional Characterization

Several studies have demonstrated that DDX39A is involved in the development and progression of various neurological disorders, including ALS. ALS is a progressive neurodegenerative disease that is characterized by the progressive loss of motor neurons.

One of the leading theories of ALS is the neurotoxicity theory, which suggests that the build-up of toxic substances in the brain, including protein aggregates, is the primary cause of the disease. The accumulation of beta-amyloid plaques, a hallmark of Alzheimer's disease, has been linked to the development of ALS.

In addition to its involvement in ALS, DDX39A has also been shown to be involved in the development of other neurological disorders, including Parkinson's disease and multiple sclerosis.

The Potential Role of DDX39A as a Drug Target

The accumulation of beta-amyloid plaques is a hallmark of neurodegenerative diseases, and efforts to treat these diseases have been largely unsuccessful. The development of drug targets, such as DDX39A, may provide a new approach to treating these diseases.

In addition to its involvement in the development of neurodegenerative diseases, DDX39A has also been shown to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and apoptosis. This suggests that it may be a useful target for the development of new drugs that can modulate these processes.

The Potential Role of DDX39A as a Biomarker

The accumulation of beta-amyloid plaques is a hallmark of neurodegenerative diseases, and efforts to treat these diseases have been largely unsuccessful. The development of drug targets, such as DDX39A, may provide a new approach to treating these diseases.

In addition to its involvement in the development of neurodegenerative diseases, DDX39A has also been shown to be involved in

Protein Name: DExD-box Helicase 39A

Functions: Involved in pre-mRNA splicing. Required for the export of mRNA out of the nucleus

The "DDX39A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX39A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets